NASDAQ:CERO CERo Therapeutics 8/22/2025 Earnings Report $0.02 -0.01 (-25.50%) As of 05/5/2026 03:57 PM Eastern ProfileEarnings HistoryForecast CERo Therapeutics EPS ResultsActual EPS-$61.71Consensus EPS -$70.23Beat/MissBeat by +$8.52One Year Ago EPSN/ACERo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACERo Therapeutics Announcement DetailsQuarterDate8/22/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsCERo Therapeutics' next earnings date is estimated for Wednesday, June 3, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile CERo Therapeutics Earnings HeadlinesCERo Therapeutics Secures Convertible Note Financing FacilityApril 14, 2026 | tipranks.comCERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 TrialApril 14, 2026 | globenewswire.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered. | Weiss Ratings (Ad)CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 TrialMarch 30, 2026 | globenewswire.comSmall-Cap healthcare stocks ranked by quant ratings after earnings seasonMarch 13, 2026 | seekingalpha.comCERo Therapeutics Holdings, Inc.: CERo Therapeutics Provides Shareholder UpdateMarch 11, 2026 | finanznachrichten.deSee More CERo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CERo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CERo Therapeutics and other key companies, straight to your email. Email Address About CERo TherapeuticsCERo Therapeutics (NASDAQ:CERO), an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.View CERo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings AppLovin (5/6/2026)ARM (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
